Categories AlphaGraphs, Consumer, Earnings
Infographic: Highlights of Kellogg Company’s Q2 2022 earnings report
Kellogg Company (NYSE: K) on Thursday reported an increase in second-quarter adjusted earnings amid an increase in revenues. The company also raised its full-year earnings guidance.
Net income, adjusted for special items, rose to $1.18 per share in the most recent quarter from $1.14 per share a year earlier and came in above the forecast. Meanwhile, second-quarter unadjusted profit dropped to $326 million or $0.95 per share from $380 million or $1.11 per share in the same period of last year.
Total sales increased 9% annually to $3.86 billion during the three-month period. The latest number also topped the market’s expectations.
Check this space to read management/analysts’ comments on Kellogg’s Q2 results
“We sustained notably strong growth momentum in snacks and emerging markets, while accelerating the recovery of supply and category share in our North America cereal business, all while leveraging productivity initiatives and revenue growth management to mitigate the impact of decades-high input cost inflation,” said Steve Cahillane, Kellogg’s CEO.
Prior Performance
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
WMT Earnings: All you need to know about Walmart’s Q2 2023 earnings results
Walmart Inc. (NYSE: WMT) reported second quarter 2023 earnings results today. Total revenue increased 8.4% year-over-year to $152.9 billion. Revenues grew 9.1% in constant currency. Consolidated net income attributable to
Rivian (RIVN) reaffirms production goals. Will it be a smooth ride?
The evolution of the electric vehicle industry accelerated in recent years even as innovations in battery technology and affordability brought EVs into the mainstream. Encouraged by the success of market
Pfizer (PFE): A look at the headwinds and tailwinds this pharma giant faces in the near term
Shares of Pfizer Inc. (NYSE: PFE) were down on Monday. The stock has dropped 15% year-to-date and there is a mixed sentiment surrounding the company’s growth prospects. Pfizer has benefited
